Analysis Of The Immunophenotype Of Leukemia Cells And Its Clinical Significance In 100 Patients With Acute Leukemia

Objective: To explore the immunophenotyp of leukemia cells and its clinical significance in acute leukemia (AL) patients.Methods : 100 patients with AL were analyzed the immunophenotype of leukemia cells by Flow Cytometry with CD45 /Side scatter (SSC) gating, and the relationship between the immunophenotype of leukemia cells and clinical prognosis of the patients was evaluated. Results The cluster of differentiation antigens (CD) expressed in 71 patients with acute myeloid leukemia (AML) were mainly CD33(90.14%), CD13(77.46%), CD117(70.42), HLA-DR(52.11%), CD15(42.25%), CD64(32.39%) and MPO(38.02%); Lymphoid antigen expression (CD7) was identified in 18.3% of AML patients, there was a statistically significant difference in the complete remission (CR) rate between CD7 + AML and CD7-AML( P < 0105). The CR rate was different between the CD56+ AML and CD56- AML patients (p<0.05). 15 patients with acute B-lymphoblastic leukemia (ALL) expressed following antigens: CD19(100%), CD79a(80%), HLA-DR(53.33%), CD34(40%), CD10(20%) and CD56(20%). Among these ALL patients, 4 patients expressed myeloid antigen CD15. There was not a statistically significant difference in the CR rate between CD15+ ALL and CD15- ALL ,although the CR rate in CD15+ALL is lower than that in CD15- ALL. 10 patients with T-ALL expressed CD3, CD2, CD7, CD34 and HLA-DR, but without the expression of myeloid CD. One patient with AUL only expressed the antigen of HLA-DR.Conclusion: (1) Immunophenotyping of leukemia cells could be helpful for classification of some specific type of acute leukemia and has important clinical significant in eva1uating the prognosis of AL.(2) The AML patients with CD7 or CD56 expression has lower CR rate. Lower CR rate was also seen in the ALL patients with myeloid antigen expression.